WPW
KNSA icon

Waldron Private Wealth’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Waldron Private Wealth’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-37,696
Closed -$406K – 407
2023
Q1 		$406K Hold
37,696
– – 0.02% 290
2022
Q4 		$484K Hold
37,696
– – 0.03% 242
2022
Q3 		$484K Hold
37,696
– – 0.03% 242
2022
Q2 		$365K Hold
37,696
– – 0.02% 274
2022
Q1 		$374K Buy
+37,696
New +$399K 0.02% 283

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Waldron Private Wealth's KNSA Position: Q2 2023 in Review

Waldron Private Wealth sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2023, closing a stake of 37,696 shares — an estimated $406K sold.

Waldron Private Wealth first reported a position in KNSA in Q1 2022 and held it in 5 quarters. The position peaked at $484K in Q4 2022. 127 funds tracked by Wall St. Rank hold KNSA as of Q2 2023.

  • Waldron Private Wealth reported no remaining Kiniksa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Waldron Private Wealth sold 37,696 Kiniksa Pharmaceuticals shares in Q2 2023, an estimated $406K.
  • Waldron Private Wealth first reported a position in Kiniksa Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Waldron Private Wealth's Kiniksa Pharmaceuticals position peaked at $484K in Q4 2022.
  • 127 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2023.

Based on Waldron Private Wealth's 13F filing for Q2 2023, filed 7 Aug 2023.